Pfiz­er ter­mi­nates PhI­II study of rare car­dio­vas­cu­lar drug picked up in $11.4B Ar­ray ac­qui­si­tion

While Pfiz­er’s $11.4 bil­lion ac­qui­si­tion of Ar­ray Bio­Phar­ma in the sum­mer of 2019 was main­ly fo­cused on on­col­o­gy, name­ly Braftovi and Mek­tovi, there were a few non-can­cer as­sets, in­clud­ing a Phase III drug be­ing test­ed in a rare car­dio­vas­cu­lar dis­ease.

The late-stage tri­al is now be­ing axed, along­side any fur­ther de­vel­op­ment of the oral small mol­e­cule, the phar­ma gi­ant dis­closed af­ter the clos­ing bell on Wednes­day. Based on an in­ter­im fu­til­i­ty analy­sis of the glob­al Phase III REALM-DCM tri­al, Pfiz­er de­ter­mined a path for­ward was not in its best in­ter­est. Pfiz­er no longer ex­pect­ed the study would meet its pri­ma­ry goal.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER